Activation of a cooperation agreement between Abu Dhabi Health Authority and AstraZeneca
A field study to evaluate the effect of the drug “Evoshield” in people with weak immunity
The study is being conducted in collaboration with Sheikh Khalifa Medical City Hospital.
From the source
The Emirate of Abu Dhabi witnessed the launch of a study of field evidence aimed at providing important realistic data on the safety and effectiveness of the long-acting antibody mixture, known as the drug “EvoShield”, developed by AstraZeneca, in protecting patients with weak immunity from symptoms of infection with “Covid-19”.
The study comes as an activation of a cooperation agreement signed by the Abu Dhabi Department of Health last year with AstraZeneca, a global company specialized in biopharmaceutical industries, with the aim of enhancing research and development efforts in health sciences and advancing innovation in health services, within the framework of the department's strategy to ensure that patients receive care. High quality hygienic.
The study is being conducted in cooperation with Sheikh Khalifa Medical City Hospital in Abu Dhabi under the supervision of the department, and extends to the end of next year, targeting 1,000 participants.
Abu Dhabi was one of the first countries in the world to receive the first shipment of "EvoShield", under the direct supervision of the department, as part of its keenness to provide the latest innovative treatments to ensure the health and safety of the population.
The multi-country prospective study will assist individuals most at risk of health in the UAE, the countries of the Middle East and Africa, by building a body of evidence to prove the effectiveness of the drug "EvoShield" in preventing infection with "Covid-19".
The undersecretary of the department, Dr. Jamal Muhammad Al-Kaabi, stressed that the health and safety of communities is a priority for the department, as it is keen to provide the latest therapeutic and preventive innovations to all, regardless of their different health needs.
About 2% of the world's population suffers from a weak immune system, and they do not respond to the "Covid-19" vaccines, or have a weak response.
These include cancer patients, people with immune diseases, people undergoing dialysis or being treated with immunosuppressive drugs, and others with weakened immunity.
The medical director at Sheikh Khalifa Medical City and the study supervisor, Dr. Nawal Al Kaabi, said that the risks of infection with “Covid-19” have never ended, especially for people with weak immunity and groups at risk, and field evidence is necessary to help us improve our understanding of the mechanisms of virus development and invent tools Additional protection for the most vulnerable groups.
Looking beyond the pandemic, this study will complement regional efforts to improve healthcare quality, advance medical data automation, and meet the growing demand for locally validated clinical data that reflects our particular demographics.
EvoShield has been granted an emergency use authorization in the United Arab Emirates, Saudi Arabia, Bahrain, Qatar and Egypt, and is the only antibody treatment that has been granted an emergency use authorization in the United States for the prevention of “Covid-19.”
Follow our latest local and sports news and the latest political and economic developments via Google news